Global RNA Interference Therapy 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI02246652

Publication Date:

February 20, 2024

Pages:

116

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

RNA Interference Therapy, or RNAi Therapy, is a cutting-edge medical approach that utilizes small RNA molecules to selectively silence or regulate targeted genes. This therapeutic method involves introducing synthetic small interfering RNA (siRNA) or microRNA (miRNA) into cells, triggering a natural biological process that inhibits the expression of disease-related genes. RNA Interference Therapy shows promise in treating various conditions, including genetic disorders, viral infections, and certain cancers. By leveraging the specificity of RNA molecules, this therapy holds the potential to revolutionize precision medicine by addressing the root causes of diseases at the genetic level, promoting targeted and personalized treatment strategies.
The global RNA Interference Therapy market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
Publisher' newest research report, the 鈥淩NA Interference Therapy Industry Forecast鈥� looks at past sales and reviews total world RNA Interference Therapy sales in 2023, providing a comprehensive analysis by region and market sector of projected RNA Interference Therapy sales for 2024 through 2030. With RNA Interference Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA Interference Therapy industry.
This Insight Report provides a comprehensive analysis of the global RNA Interference Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNA Interference Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global RNA Interference Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA Interference Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA Interference Therapy.
The RNA Interference Therapy industry is experiencing a dynamic shift towards precision medicine and targeted treatments. Advancements in understanding genetic mechanisms have fueled a surge in RNAi research and development. The trend emphasizes personalized therapies, with a focus on tackling specific gene-related disorders at the molecular level. Improvements in delivery systems, such as nanoparticle technologies, are enhancing the efficiency and specificity of RNA interference. The growing pipeline of RNAi-based drug candidates, especially in oncology and rare diseases, showcases the increasing interest and investment in this therapeutic approach. Overall, the industry trend leans towards unlocking the full potential of RNA Interference Therapy for precise and effective medical interventions.
This report presents a comprehensive overview, market shares, and growth opportunities of RNA Interference Therapy market by product type, application, key players and key regions and countries.
Segmentation by type
siRNA
miRNA
shRNA
piRNA
Segmentation by application
Cancer Treatment
Hereditary Disease
Infectious Disease
Nervous System Disease
Diseases of Immune System
Cardiovascular Disease
Metabolic Disease
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Silence Therapeutics
Arrowhead Pharmaceuticals
Janssen Research & Development
Sylentis
Sirnaomics
Dicerna Pharmaceuticals
Alnylam Pharmaceuticals
Silenseed
Vir Biotechnology
OliX Pharmaceuticals
Bio-Path Holdings
Suzhou Ribo Life Science

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global RNA Interference Therapy 麻豆原创 Size 2019-2030
2.1.2 RNA Interference Therapy 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 RNA Interference Therapy Segment by Type
2.2.1 siRNA
2.2.2 miRNA
2.2.3 shRNA
2.2.4 piRNA
2.3 RNA Interference Therapy 麻豆原创 Size by Type
2.3.1 RNA Interference Therapy 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global RNA Interference Therapy 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 RNA Interference Therapy Segment by Application
2.4.1 Cancer Treatment
2.4.2 Hereditary Disease
2.4.3 Infectious Disease
2.4.4 Nervous System Disease
2.4.5 Diseases of Immune System
2.4.6 Cardiovascular Disease
2.4.7 Metabolic Disease
2.5 RNA Interference Therapy 麻豆原创 Size by Application
2.5.1 RNA Interference Therapy 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global RNA Interference Therapy 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 RNA Interference Therapy 麻豆原创 Size by Player
3.1 RNA Interference Therapy 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global RNA Interference Therapy Revenue by Players (2019-2024)
3.1.2 Global RNA Interference Therapy Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global RNA Interference Therapy Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RNA Interference Therapy by Regions
4.1 RNA Interference Therapy 麻豆原创 Size by Regions (2019-2024)
4.2 Americas RNA Interference Therapy 麻豆原创 Size Growth (2019-2024)
4.3 APAC RNA Interference Therapy 麻豆原创 Size Growth (2019-2024)
4.4 Europe RNA Interference Therapy 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa RNA Interference Therapy 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas RNA Interference Therapy 麻豆原创 Size by Country (2019-2024)
5.2 Americas RNA Interference Therapy 麻豆原创 Size by Type (2019-2024)
5.3 Americas RNA Interference Therapy 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA Interference Therapy 麻豆原创 Size by Region (2019-2024)
6.2 APAC RNA Interference Therapy 麻豆原创 Size by Type (2019-2024)
6.3 APAC RNA Interference Therapy 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe RNA Interference Therapy by Country (2019-2024)
7.2 Europe RNA Interference Therapy 麻豆原创 Size by Type (2019-2024)
7.3 Europe RNA Interference Therapy 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa RNA Interference Therapy by Region (2019-2024)
8.2 Middle East & Africa RNA Interference Therapy 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa RNA Interference Therapy 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global RNA Interference Therapy 麻豆原创 Forecast
10.1 Global RNA Interference Therapy Forecast by Regions (2025-2030)
10.1.1 Global RNA Interference Therapy Forecast by Regions (2025-2030)
10.1.2 Americas RNA Interference Therapy Forecast
10.1.3 APAC RNA Interference Therapy Forecast
10.1.4 Europe RNA Interference Therapy Forecast
10.1.5 Middle East & Africa RNA Interference Therapy Forecast
10.2 Americas RNA Interference Therapy Forecast by Country (2025-2030)
10.2.1 United States RNA Interference Therapy 麻豆原创 Forecast
10.2.2 Canada RNA Interference Therapy 麻豆原创 Forecast
10.2.3 Mexico RNA Interference Therapy 麻豆原创 Forecast
10.2.4 Brazil RNA Interference Therapy 麻豆原创 Forecast
10.3 APAC RNA Interference Therapy Forecast by Region (2025-2030)
10.3.1 China RNA Interference Therapy 麻豆原创 Forecast
10.3.2 Japan RNA Interference Therapy 麻豆原创 Forecast
10.3.3 Korea RNA Interference Therapy 麻豆原创 Forecast
10.3.4 Southeast Asia RNA Interference Therapy 麻豆原创 Forecast
10.3.5 India RNA Interference Therapy 麻豆原创 Forecast
10.3.6 Australia RNA Interference Therapy 麻豆原创 Forecast
10.4 Europe RNA Interference Therapy Forecast by Country (2025-2030)
10.4.1 Germany RNA Interference Therapy 麻豆原创 Forecast
10.4.2 France RNA Interference Therapy 麻豆原创 Forecast
10.4.3 UK RNA Interference Therapy 麻豆原创 Forecast
10.4.4 Italy RNA Interference Therapy 麻豆原创 Forecast
10.4.5 Russia RNA Interference Therapy 麻豆原创 Forecast
10.5 Middle East & Africa RNA Interference Therapy Forecast by Region (2025-2030)
10.5.1 Egypt RNA Interference Therapy 麻豆原创 Forecast
10.5.2 South Africa RNA Interference Therapy 麻豆原创 Forecast
10.5.3 Israel RNA Interference Therapy 麻豆原创 Forecast
10.5.4 Turkey RNA Interference Therapy 麻豆原创 Forecast
10.5.5 GCC Countries RNA Interference Therapy 麻豆原创 Forecast
10.6 Global RNA Interference Therapy Forecast by Type (2025-2030)
10.7 Global RNA Interference Therapy Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Silence Therapeutics
11.1.1 Silence Therapeutics Company Information
11.1.2 Silence Therapeutics RNA Interference Therapy Product Offered
11.1.3 Silence Therapeutics RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Silence Therapeutics Main Business Overview
11.1.5 Silence Therapeutics Latest Developments
11.2 Arrowhead Pharmaceuticals
11.2.1 Arrowhead Pharmaceuticals Company Information
11.2.2 Arrowhead Pharmaceuticals RNA Interference Therapy Product Offered
11.2.3 Arrowhead Pharmaceuticals RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Arrowhead Pharmaceuticals Main Business Overview
11.2.5 Arrowhead Pharmaceuticals Latest Developments
11.3 Janssen Research & Development
11.3.1 Janssen Research & Development Company Information
11.3.2 Janssen Research & Development RNA Interference Therapy Product Offered
11.3.3 Janssen Research & Development RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Janssen Research & Development Main Business Overview
11.3.5 Janssen Research & Development Latest Developments
11.4 Sylentis
11.4.1 Sylentis Company Information
11.4.2 Sylentis RNA Interference Therapy Product Offered
11.4.3 Sylentis RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Sylentis Main Business Overview
11.4.5 Sylentis Latest Developments
11.5 Sirnaomics
11.5.1 Sirnaomics Company Information
11.5.2 Sirnaomics RNA Interference Therapy Product Offered
11.5.3 Sirnaomics RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Sirnaomics Main Business Overview
11.5.5 Sirnaomics Latest Developments
11.6 Dicerna Pharmaceuticals
11.6.1 Dicerna Pharmaceuticals Company Information
11.6.2 Dicerna Pharmaceuticals RNA Interference Therapy Product Offered
11.6.3 Dicerna Pharmaceuticals RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Dicerna Pharmaceuticals Main Business Overview
11.6.5 Dicerna Pharmaceuticals Latest Developments
11.7 Alnylam Pharmaceuticals
11.7.1 Alnylam Pharmaceuticals Company Information
11.7.2 Alnylam Pharmaceuticals RNA Interference Therapy Product Offered
11.7.3 Alnylam Pharmaceuticals RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Alnylam Pharmaceuticals Main Business Overview
11.7.5 Alnylam Pharmaceuticals Latest Developments
11.8 Silenseed
11.8.1 Silenseed Company Information
11.8.2 Silenseed RNA Interference Therapy Product Offered
11.8.3 Silenseed RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Silenseed Main Business Overview
11.8.5 Silenseed Latest Developments
11.9 Vir Biotechnology
11.9.1 Vir Biotechnology Company Information
11.9.2 Vir Biotechnology RNA Interference Therapy Product Offered
11.9.3 Vir Biotechnology RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Vir Biotechnology Main Business Overview
11.9.5 Vir Biotechnology Latest Developments
11.10 OliX Pharmaceuticals
11.10.1 OliX Pharmaceuticals Company Information
11.10.2 OliX Pharmaceuticals RNA Interference Therapy Product Offered
11.10.3 OliX Pharmaceuticals RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 OliX Pharmaceuticals Main Business Overview
11.10.5 OliX Pharmaceuticals Latest Developments
11.11 Bio-Path Holdings
11.11.1 Bio-Path Holdings Company Information
11.11.2 Bio-Path Holdings RNA Interference Therapy Product Offered
11.11.3 Bio-Path Holdings RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Bio-Path Holdings Main Business Overview
11.11.5 Bio-Path Holdings Latest Developments
11.12 Suzhou Ribo Life Science
11.12.1 Suzhou Ribo Life Science Company Information
11.12.2 Suzhou Ribo Life Science RNA Interference Therapy Product Offered
11.12.3 Suzhou Ribo Life Science RNA Interference Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Suzhou Ribo Life Science Main Business Overview
11.12.5 Suzhou Ribo Life Science Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.